Wang, T-F
Fiala, M A
Cashen, A F
Uy, G L
Abboud, C N
Fletcher, T
Wu, N
Westervelt, P
DiPersio, J F
Stockerl-Goldstein, K E
Vij, R
Article History
Received: 30 January 2014
Revised: 11 June 2014
Accepted: 13 June 2014
First Online: 28 July 2014
Competing interests
: Dr Amanda Cashen is on the Speaker’s Bureau for Celgene. Dr Stockerl-Goldstein is on the Speaker’s Bureau for Celgene and Millennium. Dr Ravi Vij received honoraria from Celgene, Onyx and Millennium, research funding from Onyx and Celgene, and is on the Speaker’s Bureau for Celgene, Millennium and Teva. The remaining authors declare no conflict of interest.